Get the latest news, insights, and market updates on ALVO (Alvotech). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Alvotech (ALVO): A Bull Case Theory
We came across a bullish thesis on Alvotech on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on ALVO. Alvotech’s share was trading at $4.60 as of December 2nd. ALVO’s trailing and forward P/E were 21.04 and 10.02 respectively according to Yahoo Finance. Alvotech is positioning itself as the “TSMC of biologics”—a fully integrated, globally […] Dec 4, 2025 - $ALVO
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
REYKJAVIK, ICELAND (November 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Commission (EC) has approved AVT03 as a biosimilar to Prolia® and Xgeva® (denosumab). The European denosumab market is currently valued at approximately US$1.2 billion across all indications, based on originator sales in the last 12 months including the second quarter of 2025[1] Nov 24, 2025 - $ALVO
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
REYKJAVIK, Iceland and LONDON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission (EC) has granted marketing authorizations in the European E Nov 20, 2025 - $ALVO
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same period last yearLicense and other revenue decreased by 13% to $182 million, compared to the same period last yearAdjusted EBITDA in the first nine months of the year was $68 million, a 21% decrease from the same period last year, driven by higher R&D investments to accelerat Nov 12, 2025 - $ALVO
Alvotech (ALVO) Reports Q3 Loss, Misses Revenue Estimates
Alvotech (ALVO) delivered earnings and revenue surprises of -140.00% and -11.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 12, 2025 - $ALVO
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron’s and Bayer’s injun Nov 10, 2025 - $ALVO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple